Seattle, March 27, 2024–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that it will release financial results for the quarter and year ended December 31, 2023 after market close on Monday, April 1, 2024. Omeros management will host a conference call and webcast on the same day at 4:30 pm ET (1:30 pm PT) to discuss financial results, recent developments and highlights.
Conference call details
To access the live webcast of the conference call online, please visit Omeros' website at https://investor.omeros.com/upcoming-events.
To access the live conference call via phone, participants must register at this link to receive a unique PIN. After registration, you have two options: (1) use the PIN provided to dial into the conference line provided at the registration site, or (2) select the “Call Me” option to immediately Your phone number will be dialed. provide. If you lose your PIN or registration confirmation email, please re-register to receive a new girlfriend PIN.
A replay of the conference call will be accessible online at https://investor.omeros.com/archived-events.
About Omeros Co., Ltd.
Omeros is committed to discovering, developing and commercializing small molecule and protein therapeutics for large market and rare diseases, targeting complement-mediated diseases, cancer, and immune diseases such as addictive and obsessive-compulsive disorders. is an innovative biopharmaceutical company. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and has a pending biologics license application (BLA) with the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). is subject to. Omeros' long-acting MASP-2 inhibitor OMS1029 is currently in Phase 1 clinical trials. Omeros' OMS906, an inhibitor of MASP-3, a key activator of the alternative complement pathway, has progressed in clinical programs for paroxysmal nocturnal hemoglobinuria (PNH), a complement 3 (C3) glomerulopathy. I am. Funded by the National Institute on Drug Abuse, Omeros' major phosphodiesterase 7 (PDE7) inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder (CUD), a major addiction as well as other addictions. It is also being developed as a therapeutic drug. Complications of movement disorder treatment. Omeros is also advancing a broad portfolio of new immuno-oncology programs consisting of two cellular and three molecular platforms. For more information about Omeros and its programs, please visit www.omeros.com.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240327216351/ja/
contact address
jennifer cook williams
Cook Williams Communications, Inc.
For investors and media
IR@omeros.com
